Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Item 9 Labs (INLB) EBITDA (2016 - 2023)

Item 9 Labs' EBITDA history spans 12 years, with the latest figure at -$2.9 million for Q2 2023.

  • For Q2 2023, EBITDA rose 23.36% year-over-year to -$2.9 million; the TTM value through Jun 2023 reached $9.6 million, up 168.97%, while the annual FY2022 figure was $6.8 million, 226.77% up from the prior year.
  • EBITDA reached -$2.9 million in Q2 2023 per INLB's latest filing, down from -$1.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $15.4 million in Q3 2022 to a low of -$8.2 million in Q3 2019.
  • Average EBITDA over 5 years is -$634881.1, with a median of -$1.0 million recorded in 2019.
  • Peak YoY movement for EBITDA: crashed 2414.86% in 2019, then skyrocketed 385.03% in 2022.
  • A 5-year view of EBITDA shows it stood at -$1.2 million in 2019, then soared by 71.48% to -$333605.0 in 2020, then tumbled by 518.47% to -$2.1 million in 2021, then rose by 23.16% to -$1.6 million in 2022, then crashed by 82.0% to -$2.9 million in 2023.
  • Per Business Quant, the three most recent readings for INLB's EBITDA are -$2.9 million (Q2 2023), -$1.3 million (Q1 2023), and -$1.6 million (Q4 2022).